Roivant Sciences (Switzerland)

Roivant describes itself as reinventing the discovery, development, and commercialization of new medicines. It develops transformative medicines and technologies by building agile, focused companies called Vants, and it reports 12 positive Phase 3 trials since 2019 and 09 FDA approvals. Its family of companies spans multiple therapeutic areas, modalities, and technologies, and includes Immunovant, Priovant, and Pulmovant.

Roivant presents itself as reinventing the discovery, development, and commercialization of new medicines. It develops transformative medicines and technologies by building agile, focused companies called Vants. The company states that it has had 12 positive Phase 3 trials since 2019 and 09 FDA approvals. Its model aligns incentives to drive fast, high-quality execution and rigorous capital allocation, and it employs technology across discovery, development, and commercialization. Its family of companies spans multiple therapeutic areas, modalities, and technologies, including Immunovant, Priovant, and Pulmovant.

Reinventing the discovery, development, and commercialization of new medicines

1. 1Roivantroivant.com
2. 2Company Overview | Roivantroivant.com
3. 3Corporate Social Responsibility | Roivantroivant.com
4. 4Our Companies | Roivantroivant.com